C-Peptide and its correlation to parameters of insulin resistance in the metabolic syndrome

CNS and Neurological Disorders - Drug Targets

Volumn 10, Issue 8, 2011, Pages 921-927

  Banu, Shaheena ^a   Jabir, Nasimudeen R ^b   Manjunath, C N ^a   Shakil, Shazi ^b   Kamal, Mohammad A ^b  

^a SRI JAYADEVA INSTITUTE OF CARDIOVASCULAR SCIENCES AND RESEARCH   (India)

^b KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

Author keywords

C peptide; Insulin resistance; Metabolic syndrome; Type 2 Diabetes Mellitus

Indexed keywords

C PEPTIDE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANTHROPOMETRIC PARAMETERS; ARTICLE; BLOOD SAMPLING; BODY HEIGHT; BODY MASS; BODY WEIGHT; CELL FUNCTION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NON INSULIN DEPENDENT DIABETES MELLITUS; PANCREAS ISLET BETA CELL; PATIENT ASSESSMENT; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; TRIACYLGLYCEROL BLOOD LEVEL; WAIST CIRCUMFERENCE;

EID: 84857747894     PISSN: 18715273     EISSN: 19963181     Source Type: Journal    
DOI: 10.2174/187152711799219271     Document Type: Article

References (41)

1. McCullough, A.J. Epidemiology of the metabolic syndrome in the USA. J. Dig. Dis., 2011, 12(5), 333-340.
2. Tan, Y.; Kamal, M.A.; Wang, Z.Z.; Xiao, W.; Seale, J.P.; Qu, X. Chinese herbal extracts (SK0506) as a potential candidate for the therapy of the metabolic syndrome. Clin. Sci. (Lond.), 2011, 120(7), 297-305.
3. Palmieri, V.O.; DeRasmo, D.; Signorile, A.; Sardanelli, AM.; Grattagliano, I.; Minerva, F.; Cardinale, G.; Portincasa, P.; Papa, S.; Palasciano, G. T16189C mitochondrial DNA variant is associated with metabolic syndrome in Caucasian subjects. Nutrition, 2011, 27(7-8), 773-777.
4. Sato, N.; Takeda, S.; Uchio, Y.K.; Ueda, H.; Fujisawa, T.; Rakugi, H.; Morishita, R. Role of insulin signaling in the interaction between Alzheimer disease and diabetes mellitus: a missing link to therapeutic potential. Curr. Aging Sci., 2011, 4(2), 118-127.
5. Jellinger, K.A. Alzheimer 100 - highlights in the history of Alzheimer research. J. Neural Transm., 2006, 113, 1603-1623.
6. Li, L.; Holscher, C. Common pathological processes in Alzheimer disease and Type 2 diabetes. A review. Brain Res. Rev., 2007, 56, 384-402.
7. Ahmed, I.; Goldstein, B.J. Cardiovascular risk in the spectrum of type 2 diabetes mellitus. Mt. Sinai J. Med., 2006, 73, 759-768.
8. Belfki, H.; Ben Ali, S.; Bougatef, S.; Ben Ahmed, D.; Haddad, N.; Jmal, A.; Abdennebi, M.; Ben Romdhane, H. Association between C-Reactive Protein and Type 2 Diabetes in a Tunisian Population. Inflammation, 2011, [Epub ahead of print].
9. Nakanishi, N.; Shiraishi, T.; Wada, M. Association between Creactive protein and insulin resistance in a Japanese population: the Minoh Study. Intern. Med., 2005, 44(6), 542-547.
10. Das, U.N. Acetylcholinesterase and butyrylcholinesterase as possible markers of low-grade systemic inflammation. Med. Sci. Monit., 2007, 13, 214-221.
11. Shoelson, S.E.; Lee, J.; Goldfine, A.B.; Inflammation and insulin resistance. J. Clin. Invest., 2006, 116, 1793-1801.
12. Grundy, S.M.; Cleeman, J.I.; Daniels, S.R.; Donato, K.A.; Eckel, R.H.; Franklin, B.A.; Gordon, D.J.; Krauss, R.M.; Savage, P.J.; Smith, S.C.; Spertus, J.A.; Costa, F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation., 2005, 112, 2735-2752.
13. Vasic, D.; Marx, N.; Sukhova, G.; Bach, H.; Durst, R.; Grüb, M.; Hausauer, A.; Hombach, V.; Rottbauer, W.; Walcher D. Cpeptide promotes lesion development in a mouse model of arteriosclerosis. J. Cell Mol. Med., 2011, [Epub ahead of print].
14. Nikolaus, M.; Daniel W. C-Peptide and atherogenesis: C-peptide as a mediator of lesion development in patients with type 2 Diabetes Mellitus?. Exp. Diabetes Res., 2008, 2008, 385108.
15. Faber, O.K.; Binder, C. C-peptide:An index of insulin secretion. Diabetes Metab. Rev., 1986, 2(3-4), 331-345.
16. Sherry, N.A.; Tsai, E.B.; Herold, K.C. Natural history of beta-cell function in type 1 diabetes. Diabetes, 2005, 54(2) S32-S39.
17. Brandenburg, D. History and diagnostic significance of C-peptide. Exp. Diabetes Res., 2008, 576862.
18. Meigs, J.B. Invited commentary: insulin resistance syndrome? Syndrome X? Multiple metabolic syndrome? A syndrome at all? Factor analysis reveals patterns in the fabric of correlated metabolic risk factors. Am. J. Epidemic., 2000, 152(10), 908-911.
19. Johnson, L.W.; Weinstock, R.S. The metabolic syndrome: concepts and controversy. Mayo Clin. Proc., 2006, 81(12), 1615-1620.
20. Grundy, S.M.; Hansen, B.; Smith, S.C.; Cleeman, J.I.; Kahn, R.A. Clinical management of metabolic syndrome: report of the American Heart Association/National Heart, Lung, and blood Institute/American Association conference on scientific issues related to management. Circulation, 2004, 109(4), 551-556.
21. Bruno, G.; Merletti, F.; Biggeri, A.; Bargero, G.; Ferrero, S.; Runzo, C.; Prina, C.S.; Pagana, G.; Cavallo, P.P. Metabolic syndrome as a predictor of all cause and cardiovascular mortality in type2 diabetes: the Casele Monferrato Study. Diabetes Care, 2004, 27(11), 2689-2694.
22. Matthews, D.R.; Hosker, J.P.; Rudenski, A.S.; Naylor, B.A.; Treacher, D.F.; Turner, R.C. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia, 1985, 28(7), 412-419.
23. Levy, J.C.; Matthews, D.R.; Hermans, M.P. Correct homeostasis model assessment (HOMA) evaluation uses the computer program. Diabetes Care, 1998, 21(12), 2191-2192.
24. Grundy, S.M.; Brewer, H.B.; Cleeman, J.I.; Smith, S.C.; Lenfant, C.; American Heart Association.; National Heart, Lung, and Blood Institute. Definition of metabolic syndrome: Report of the National Heart, Lung, and Blood Institute/American Heart Association conference on scientific issues related to definition. Circulation, 2004, 109(3), 433-438.
25. Alberti, K.; Zimmet, P.; Shaw, J. Metabolic syndrome-a new world wide definition. A Consensus Statement from the International Diabetes Federation. Diabet. Med., 2006, 23, 469-480.
26. Misra, A.; Vikram, N.K. Insulin resistance syndrome (metabolic syndrome) and obesity in Asian Indians: evidence and implication. Nutrition, 2004, 20, 482-491.
27. Clauson, P.; Lmnarsson, R.; Gottsaler, A.; Sundkvist, G.; Grill, V. Relationship between diabetes duration, metabolic control and beta-cell function in a representative population of type-2 diabetic patients in Sweden. Diabet. Med., 1994, 11, 794-801.
28. Poitout, V.; Robertson, R.P. Miniview: Secondary beta-cell failure in type2 Dm -a convergence of glucotoxicity and lipotoxicity. Endocrinology, 2002, 143, 339-342.
29. Gonen, B.; Goldman, J.; Baldwin, D.; Goldberg, R.B.; Ryan, W.G.; Blix, P.M.; Schanzlin, D.; Fritz, K.J.; Rubenstein, A.H. Metabolic control in diabetic patients. Effect of insulin-secretory reserve (measured by plasma C-peptide levels) and circulating insulin antibodies. Diabetes, 1979, 28(8), 749-753.
30. Pelikanova, T.; Kohout, M.; Valek, J.; Base, J.; Kadova, L. Insulin secretion and insulin action related to the serum phospholipid fatty acid pattern in healthy men. Metabolism, 1989, 38,188-192.
31. Sayer, A.A.; Syddall, H.E.; Dennison, E.M.; Gilby, H.J.; Duggleby, S.L.; Copper, C.; Barker, D.J.; Phillips, D.I. Birthweight, weight at 1year of age and body composition in older men: findings from Hertfordshire Cohert Study. Am. J. Clin. Nutr., 2004, (1), 199-203.
32. Bo, S.; Cavallo-Perin, P.; Gentile, L.; Repetti, E.; Pagano, G. Relationship of residual beta-cell function, metabolic control and chronic complications in type 2 diabetes mellitus. Acta Diabetol., 2000, 37(3), 125-129,
33. Craft, S. Insulin resistance and Alzheimer's disease pathogenesis: potential mechanisms and implications for treatment. Curr. Alzheimer Res., 2007, 4(2), 147-152.
34. Craft, S. Insulin resistance syndrome and Alzheimer's disease: ageand obesity-related effects on memory, amyloid, and inflammation. Neurobiol. Aging, 2005, 26(1), 65-69.
35. Lee, Y.S.; Li, P.; Huh, J.Y.; Hwang, I.J.; Lu, M.; Kim, J.I.; Ham, M.; Talukdar, S.; Chen, A.; Lu, W.J.; Bandyopadhyay, G.K.; Schwendener, R.; Olefsky, J.; Kim, J.B. Inflammation is necessary for long-term but not short-term high-fat diet-induced insulin resistance. Diabetes, 2011, 60(10), 2474-2483.
36. Murray, I.V.; Proza, J.F.; Sohrabji, F.; Lawler, J.M. Vascular and metabolic dysfunction in Alzheimer's disease: a review. Exp. Biol. Med. (Maywood), 2011, 236(7), 772-782.
37. Matsuzaki, T.; Sasaki, K.; Hata, J.; Hirakawa, Y.; Fujimi, K.; Ninomiya, T.; Suzuki, SO.; Kanba, S.; Kiyohara, Y.; Iwaki, T. Association of Alzheimer disease pathology with abnormal lipid metabolism: The Hisayama Study. Neurology, 2011, 77(11), 1068-1075.
38. Tan, Y.; Sun, L.Q.; Kamal, M.A.; Wang, X.; Seale, J.P; Qu, X. Suppression of retinol-binding protein 4 with RNA oligonucleotide prevents high-fat diet-induced metabolic syndrome and nonalcoholic fatty liver disease in mice. Biochim. Biophys. Acta, 2011, 1811(12), 1045-1053.
39. Okereke, O.I.; Selkoe, D.J.; Pollak, M.N.; Stampfer, M.J.; Hu, F.B.; Hankinson, S.E.; Grodstein, F. A profile of impaired insulin degradation in relation to late-life cognitive decline: a preliminary investigation. Int. J. Geriatr. Psychiatry, 2009, 24(2), 177-182.
40. Granic, I.; Dolga, A.M.; Nijholt, I.M.; Van Dijk, G.; Eisel, U.L. Inflammation and NF-kappaB in Alzheimer's disease and diabetes. J. Alzheimers Dis., 2009, 16(4), 809-821.
41. Yamamoto, Y.; Gaynor, R.B. Role of the NF-kappaB pathway in the pathogenesis of human disease states. Curr. Mol. Med., 2001, 1(3), 287-296.